MediWound Q3 2026 Earnings Call - MEDIWOUND LTD

Explicit Guidance:

• Revenue Outlook: No explicit financial guidance provided for FY2026 or FY2027 due to uncertainty regarding the funding timeline for a planned U.S.-based manufacturing facility. Management states, "our 2026 Revenue Outlook depends on these ongoing discussions" regarding substantial anticipated revenue tied to development services for this project.
• Cash Flow & Balance Sheet: Following a $17.25 million underwritten public offering closed in November 2026, the company holds $28.4 million in cash, cash equivalents, and deposits as of September 30, 2026 (down from $53.6 million at year-end 2025).
• Capital Expenditure/Operating Expenses: R&D spending on the S-Correct Phase III trial is expected to "decline substantially" upon completion of enrollment. SG&A expenses are projected to remain lower than prior years if marketing expenses do not increase.

Business-Segment Outlook:

• S-Correct (SCRX):
  • Clinical Trials (VLU): Enrollment is on track to complete the pre-specified interim sample size reassessment by the end of Q1 2027. Top-line results for the Phase III Value trial in venous leg ulcers are expected by mid-2027, assuming base case enrollment and no sample size expansion.
  • New Indications: Preparation for Phase III trials in diabetic foot ulcers (DFU) and pressure ulcers is ongoing. The pressure ulcer study (investigator-initiated) is expected to launch in the "next few weeks." The DFU study (50 patients, double-blinded) is supported by the European Innovation Council and strategic collaborators.
  • Commercial Potential: Projected US peak sales of approximately $1 billion across venous leg ulcers, diabetic foot ulcers, and pressure ulcers.
• NexoBrid:
  • Commercial: U.S. commercial trajectory is strengthening with the highest quarterly revenue to date in the first nine months of 2026. Government procurement under the BARDA contract began Q3 2026 and is expected to continue through Q4 2027 and Q1 2025 (noted as likely Q1 2026 based on context).
  • R&D: Two development programs under the VeriCell Master Service Agreement are advancing: expansion to acute trauma injuries and a new stable formulation. The Department of War awarded $3.3 million (total budget $21.8 million) to advance the room-temperature stable formulation for submission of an Investigational New Drug (IND) application.

Market and Competitive Outlook:

• Supply-Demand Dynamics: Global demand for NexoBrid currently exceeds manufacturing capacity. The company is "selling every unit we can manufacture," with supply constraints limiting ability to meet needs in Europe, Japan, and other markets.
• Competitive Landscape: Management positions S-Correct as the only late-stage BLA candidate for its class following CMS reimbursement changes for older products. They highlight a significant efficacy advantage (4-5 days vs. 4-8 weeks) over the incumbent Santil, noting that 8 out of the 9 largest wound care companies are currently collaborating with MediWound.

Macro / Industry Outlook:

• Regulatory Environment: NexoBrid facility received GMP certification valid for two additional years from the FDA, Israeli Ministry of Health, and EMA.
• Pricing/Reimbursement: Shift in CMS reimbursement for legacy products (Skin Substitute) is driving large wound care companies toward BLA-approved products with established reimbursement paths, positioning S-Correct favorably.

Strategic Initiatives:

• Capacity Expansion: Modifications to the expanded NexoBrid manufacturing facility are expected to be completed in Q4 2026. Commercial supply from this facility is targeted for the second half of 2027, pending regulatory approval and inspection.
• U.S. Manufacturing: Actively pursuing funding and partnership for a planned U.S.-based manufacturing facility, which is critical for future revenue realization and capacity expansion.
• R&D Collaboration: Advancing NexoBridge programs via BARDA contracts and Department of War funding to broaden applications in civilian and military burn care.

Risks and Headwinds to Outlook:

• Funding Uncertainty: The realization of 2026 revenue is contingent on securing funding for the U.S. manufacturing facility; management cannot confirm "when or whether funding will be secured."
• Clinical Execution: While enrollment confidence is "very comfortable" (95% of sites open), trial progress depends on the DSMB's interim sample size reassessment (Q1 2027) which could result in an increased sample size requirement.
• Regulatory & Manufacturing: Commercial supply from the expanded facility remains "subject to regulatory approval," which could delay the H2 2027 timeline.
• Clinical Endpoints: The DSMB will specifically assess the time to facilitate wound closure (the co-primary endpoint) to determine if study modifications are necessary.

Management Tone on the Future:

• Confidence Level: High confidence regarding S-Correct enrollment completion (Q1 2027) and trial integrity, though cautious on financial guidance due to external funding variables.
• Strategic Focus: Priorities are clearly defined: complete the Value interim assessment/enrollment and support NexoBrid growth via capacity expansion.
• Flexibility: Management expresses flexibility regarding S-Correct commercialization strategy (partnership vs. independent launch), indicating readiness to decide post-data readout.

Miscellaneous:

• Timeline Discrepancy Note: The transcript contains a reference to government procurement continuing into "Q1 2025," which logically corresponds to Q1 2026 given the Q3 2026 reporting period and the context of the 2026 fiscal year.
• Warrant Activity: All board members, the founder, and the CEO exercised warrants and agreed to lock-up restrictions during the recent offering.